226-104US SEQ LIST.txt

SEQUENCE LISTING

<110> DUFT, BRADFORD J.
KOLTERMAN, ORVILLE G.

<120> METHODS FOR TREATING OBESITY

<130> 18528.231

<140> US 08/870,762
<141> 1997-06-06

<160> 25

<170> PatentIn version 3.3

<210> 1
<211> 37
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide construct

<400> 1

Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu
1 5 10 15

Val His Ser Ser Asn Asn Phe Gly Pro Ile Leu Pro Pro Thr Asn Val
20 25 30

Gly Ser Asn Thr Tyr
35

<210> 2
<211> 37
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide construct

<400> 2

Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu
1 5 10 15

Val Arg Ser Ser Asn Asn Phe Gly Pro Ile Leu Pro Pro Thr Asn Val
20 25 30

Gly Ser Asn Thr Tyr
35

<210> 3
<211> 37
<212> PRT

<213> Artificial Sequence

<220>
<223> Synthetic peptide construct

<400> 3

Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu
1 5 10 15

Val Arg Ser Ser Asn Asn Phe Gly Pro Ile Leu Pro Ser Thr Asn Val
20 25 30

Gly Ser Asn Thr Tyr
35

<210> 4
<211> 37
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide construct

<400> 4

Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu
1 5 10 15

Val His Ser Ser Asn Asn Phe Gly Ala Ile Leu Pro Ser Thr Asn Val
20 25 30

Gly Ser Asn Thr Tyr
35

<210> 5
<211> 37
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide construct

<400> 5

Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu
1 5 10 15

Val His Ser Ser Asn Asn Phe Gly Pro Val Leu Pro Pro Thr Asn Val
20 25 30

Gly Ser Asn Thr Tyr
35

<210> 6
<211> 37
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide construct

<220>
<221> misc_feature
<223> 2,7-Cyclo bridge

<400> 6

Lys Asp Asn Thr Ala Thr Lys Ala Thr Gln Arg Leu Ala Asn Phe Leu
1 5 10 15

Val His Ser Ser Asn Asn Phe Gly Ala Ile Leu Ser Ser Thr Asn Val
20 25 30

Gly Ser Asn Thr Tyr
35

<210> 7
<211> 36
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide construct

<400> 7

Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu Val
1 5 10 15

His Ser Ser Asn Asn Phe Gly Ala Ile Leu Ser Ser Thr Asn Val Gly
20 25 30

Ser Asn Thr Tyr
35

<210> 8
<211> 37
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide construct

<400> 8

Ala Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu
1 5 10 15

Val His Ser Ser Asn Asn Phe Gly Ala Ile Leu Ser Ser Thr Asn Val
20 25 30

Gly Ser Asn Thr Tyr
35

<210> 9
<211> 37
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide construct

<400> 9

Ser Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu
1 5 10 15

Val His Ser Ser Asn Asn Phe Gly Ala Ile Leu Ser Ser Thr Asn Val
20 25 30

Gly Ser Asn Thr Tyr
35

<210> 10
<211> 37
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide construct

<400> 10

Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu
1 5 10 15

Val His Ser Ser Asn Asn Phe Gly Ala Ile Leu Ser Pro Thr Asn Val
20 25 30

Gly Ser Asn Thr Tyr
35

<210> 11
<211> 37
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide construct

<400> 11

Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu

1 5 10 15

Val His Ser Ser Asn Asn Phe Gly Pro Ile Leu Pro Ser Thr Asn Val
20 25 30

Gly Ser Asn Thr Tyr
35

<210> 12
<211> 36
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide construct

<400> 12

Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu Val
1 5 10 15

His Ser Ser Asn Asn Phe Gly Pro Ile Leu Pro Ser Thr Asn Val Gly
20 25 30

Ser Asn Thr Tyr
35

<210> 13
<211> 36
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide construct

<400> 13

Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu Val
1 5 10 15

Arg Ser Ser Asn Asn Phe Gly Pro Ile Leu Pro Ser Thr Asn Val Gly
20 25 30

Ser Asn Thr Tyr
35

<210> 14
<211> 36
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide construct

<400> 14

Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu Val
1 5 10 15

Arg Ser Ser Asn Asn Phe Gly Pro Ile Leu Pro Pro Thr Asn Val Gly
20 25 30

Ser Asn Thr Tyr
35

<210> 15
<211> 36
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide construct

<400> 15

Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu Val
1 5 10 15

His Ser Ser Asn Asn Phe Gly Pro Ile Leu Pro Pro Thr Asn Val Gly
20 25 30

Ser Asn Thr Tyr
35

<210> 16
<211> 30
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide construct

<400> 16

Val Thr His Arg Leu Ala Gly Leu Leu Ser Arg Ser Gly Gly Val Val
1 5 10 15

Lys Asn Asn Phe Val Pro Thr Asn Val Gly Ser Lys Ala Phe
20 25 30

<210> 17
<211> 37
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide construct

<220>
<221> MISC_FEATURE
<223> c-term may be amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, aralkylamino, alkyloxy, aryloxy, or aralkyloxy

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Lys, Ala, Ser, or not present

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Variable amino acid

<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> Variable amino acid

<220>
<221> MISC_FEATURE
<222> (13)..(13)
<223> Ala, Ser, or Thr

<220>
<221> MISC_FEATURE
<222> (17)..(17)
<223> Val, Leu, or Ile

<220>
<221> MISC_FEATURE
<222> (18)..(18)
<223> His or Arg

<220>
<221> MISC_FEATURE
<222> (19)..(19)
<223> Ser or Thr

<220>
<221> MISC_FEATURE
<222> (20)..(20)
<223> Ser, Thr, Gln, or Asn

<220>
<221> MISC_FEATURE
<222> (21)..(21)
<223> Asn, Gln, or His

<220>
<221> MISC_FEATURE
<222> (23)..(23)
<223> Phe, Leu, or Tyr

<220>
<221> MISC_FEATURE
<222> (26)..(26)
<223> Ile, Val, Ala, or Leu

<220>
<221> MISC_FEATURE
<222> (29)..(29)

<223> Ser, Pro, or Thr

<220>
<221> MISC_FEATURE
<222> (31)..(31)
<223> Asn, Asp, or Gln

<400> 17

Xaa Xaa Asn Thr Ala Thr Xaa Ala Thr Gln Arg Leu Xaa Asn Phe Leu
1 5 10 15

Xaa Xaa Xaa Xaa Xaa Asn Xaa Gly Pro Xaa Leu Pro Xaa Thr Xaa Val
20 25 30

Gly Ser Asn Thr Tyr
35

<210> 18
<211> 37
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide construct

<220>
<221> MISC_FEATURE
<223> c-term may be amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, aralkylamino, alkyloxy, aryloxy, or aralkyloxy

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Lys, Ala, Ser, or not present

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Variable amino acid

<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> Variable amino acid

<220>
<221> MISC_FEATURE
<222> (13)..(13)
<223> Ala, Ser, or Thr

<220>
<221> MISC_FEATURE
<222> (17)..(17)
<223> Val, Leu, or Ile

<220>
<221> MISC_FEATURE
<222> (18)..(18)

<223> His or Arg

<220>
<221> MISC_FEATURE
<222> (19)..(19)
<223> Ser or Thr

<220>
<221> MISC_FEATURE
<222> (20)..(20)
<223> Ser, Thr, Gln, or Asn

<220>
<221> MISC_FEATURE
<222> (21)..(21)
<223> Asn, Gln, or His

<220>
<221> MISC_FEATURE
<222> (23)..(23)
<223> Phe, Leu, or Tyr

<220>
<221> MISC_FEATURE
<222> (26)..(26)
<223> Ile, Val, Ala, or Leu

<220>
<221> MISC_FEATURE
<222> (28)..(28)
<223> Ser, Pro, Leu, Ile or Thr

<220>
<221> MISC_FEATURE
<222> (31)..(31)
<223> Asn, Asp, or Gln

<400> 18

Xaa Xaa Asn Thr Ala Thr Xaa Ala Thr Gln Arg Leu Xaa Asn Phe Leu
1 5 10 15

Xaa Xaa Xaa Xaa Xaa Asn Xaa Gly Pro Xaa Leu Xaa Pro Thr Xaa Val
20 25 30

Gly Ser Asn Thr Tyr
35

<210> 19
<211> 37
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide construct

<220>
<221> MISC_FEATURE
<223> c-term may be amino, alkylamino, dialkylamino, cycloalkylamino,

arylamino, aralkylamino, alkyloxy, aryloxy, or aralkyloxy

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Lys, Ala, Ser, or not present

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Variable amino acid

<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> Variable amino acid

<220>
<221> MISC_FEATURE
<222> (13)..(13)
<223> Ala, Ser, or Thr

<220>
<221> MISC_FEATURE
<222> (17)..(17)
<223> Val, Leu, or Ile

<220>
<221> MISC_FEATURE
<222> (18)..(18)
<223> His or Arg

<220>
<221> MISC_FEATURE
<222> (19)..(19)
<223> Ser or Thr

<220>
<221> MISC_FEATURE
<222> (20)..(20)
<223> Ser, Thr, Gln, or Asn

<220>
<221> MISC_FEATURE
<222> (21)..(21)
<223> Asn, Gln, or His

<220>
<221> MISC_FEATURE
<222> (23)..(23)
<223> Phe, Leu, or Tyr

<220>
<221> MISC_FEATURE
<222> (25)..(25)
<223> Ala or Pro

<220>
<221> MISC_FEATURE
<222> (26)..(26)
<223> Ile, Val, Ala, or Leu

<220>

<221> MISC_FEATURE
<222> (31)..(31)
<223> Asn, Asp, or Gln

<400> 19

Xaa Xaa Asn Thr Ala Thr Xaa Ala Thr Gln Arg Leu Xaa Asn Phe Leu
1 5 10 15

Xaa Xaa Xaa Xaa Xaa Asn Xaa Gly Xaa Xaa Leu Pro Pro Thr Xaa Val
20 25 30

Gly Ser Asn Thr Tyr
35

<210> 20
<211> 37
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide construct

<220>
<221> MISC_FEATURE
<223> c-term may be amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, aralkylamino, alkyloxy, aryloxy, or aralkyloxy

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Lys, Ala, Ser, or not present

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Variable amino acid

<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> Variable amino acid

<220>
<221> MISC_FEATURE
<222> (13)..(13)
<223> Ala, Ser, or Thr

<220>
<221> MISC_FEATURE
<222> (17)..(17)
<223> Val, Leu, or Ile

<220>
<221> MISC_FEATURE
<222> (18)..(18)
<223> His or Arg

<220>

<221> MISC_FEATURE
<222> (19)..(19)
<223> Ser or Thr

<220>
<221> MISC_FEATURE
<222> (20)..(20)
<223> Ser, Thr, Gln, or Asn

<220>
<221> MISC_FEATURE
<222> (21)..(21)
<223> Asn, Gln, or His

<220>
<221> MISC_FEATURE
<222> (23)..(23)
<223> Phe, Leu, or Tyr

<220>
<221> MISC_FEATURE
<222> (26)..(26)
<223> Ile, Val, Ala, or Leu

<220>
<221> MISC_FEATURE
<222> (31)..(31)
<223> Asn, Asp, or Gln

<400> 20

Xaa Xaa Asn Thr Ala Thr Xaa Ala Thr Gln Arg Leu Xaa Asn Phe Leu
1 5 10 15

Xaa Xaa Xaa Xaa Xaa Asn Xaa Gly Pro Xaa Leu Pro Pro Thr Xaa Val
20 25 30

Gly Ser Asn Thr Tyr
35

<210> 21
<211> 37
<212> PRT
<213> Rattus norvegicus

<220>
<221> misc_feature
<223> 2,7-Cylco bridge

<400> 21

Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu
1 5 10 15

Val Arg Ser Ser Asn Asn Leu Gly Pro Val Leu Pro Pro Thr Asn Val
20 25 30

Gly Ser Asn Thr Tyr
35

<210> 22
<211> 37
<212> PRT
<213> Homo sapiens

<400> 22

Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu
1 5 10 15

Val His Ser Ser Asn Asn Phe Gly Ala Ile Leu Ser Ser Thr Asn Val
20 25 30

Gly Ser Asn Thr Tyr
35

<210> 23
<211> 37
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide construct

<220>
<221> MISC_FEATURE
<223> c-term may be hydroxy, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, aralkylamino, alkyloxy, aryloxy, or aralkyloxy

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Lys, Ser, Ala, acetylated Lys, or not present

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Variable amino acid

<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> Variable amino acid

<220>
<221> MISC_FEATURE
<222> (13)..(13)
<223> Ala, Ser, or Thr

<220>
<221> MISC_FEATURE
<222> (17)..(17)
<223> Val, Leu, or Ile

<220>
<221> MISC_FEATURE
<222> (18)..(18)
<223> His or Arg

<220>
<221> MISC_FEATURE
<222> (19)..(19)
<223> Ser or Thr

<220>
<221> MISC_FEATURE
<222> (20)..(20)
<223> Ser, Thr, Gln, or Asn

<220>
<221> MISC_FEATURE
<222> (21)..(21)
<223> Asn, Gln, or His

<220>
<221> MISC_FEATURE
<222> (23)..(23)
<223> Phe, Leu, or Tyr

<220>
<221> MISC_FEATURE
<222> (25)..(25)
<223> Ala or Pro

<220>
<221> MISC_FEATURE
<222> (26)..(26)
<223> Ile, Val, Ala, or Leu

<220>
<221> MISC_FEATURE
<222> (28)..(28)
<223> Ser, Pro, Leu, Ile, or Thr

<220>
<221> MISC_FEATURE
<222> (29)..(29)
<223> Ser, Pro, or Thr

<220>
<221> MISC_FEATURE
<222> (31)..(31)
<223> Asn, Asp, or Gln

<400> 23

Xaa Xaa Asn Thr Ala Thr Xaa Ala Thr Gln Arg Leu Xaa Asn Phe Leu
1 5 10 15

Xaa Xaa Xaa Xaa Xaa Asn Xaa Gly Xaa Xaa Leu Xaa Xaa Thr Xaa Val
20 25 30

Gly Ser Asn Thr Tyr
35

<210> 24
<211> 37
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide construct

<220>
<221> MISC_FEATURE
<222> (11)..(11)
<223> Arg is a D amino acid residue

<400> 24

Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu
1 5 10 15

Val His Ser Ser Asn Asn Phe Gly Ala Ile Leu Ser Ser Thr Asn Val
20 25 30

Gly Ser Asn Thr Tyr
35

<210> 25
<211> 36
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide construct

<400> 25

Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu Val
1 5 10 15

His Ser Ser Asn Asn Phe Gly Pro Val Leu Pro Pro Thr Asn Val Gly
20 25 30

Ser Asn Thr Tyr
35